Edition:
India

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

38.71USD
17 Nov 2017
Change (% chg)

$1.74 (+4.71%)
Prev Close
$36.97
Open
$36.70
Day's High
$38.84
Day's Low
$36.70
Volume
158,574
Avg. Vol
136,685
52-wk High
$40.35
52-wk Low
$23.07

Select another date:

Wed, Nov 15 2017

BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​

* Acceleron announces preclinical results in pulmonary arterial hypertension at the American Heart Association 2017 Scientific Sessions

BRIEF-Acceleron Pharma qtrly net loss per share $0.65

* Acceleron Pharma reports third quarter 2017 operational and financial results

BRIEF-Acceleron announces pricing of public offering of common stock

* Acceleron announces pricing of public offering of common stock

BRIEF-Acceleron announces proposed public offering of common stock

* Acceleron announces proposed public offering of common stock

BRIEF-Acceleron Pharma Q2 loss per share $0.77

* Acceleron Pharma reports second quarter 2017 operational and financial results

BRIEF-Acceleron announces first patient treated in phase 2 clinical trial of ACE-083

* Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease Source text for Eikon: Further company coverage:

BRIEF-Acceleron announces top-line results from dart phase 2 study of dalantercept

* Acceleron announces top-line results from dart phase 2 study of dalantercept in advanced renal cell carcinoma

BRIEF-Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept

* Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia

Select another date: